Taysha Gene Therapies, Inc.
TSHA
$3.27
$0.113.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.88M | -21.53M | -18.79M | -25.52M | -20.93M |
| Total Depreciation and Amortization | 277.00K | 283.00K | 304.00K | 294.00K | 322.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.20M | 3.78M | 2.77M | 9.50M | 3.38M |
| Change in Net Operating Assets | 2.23M | -4.56M | -2.60M | -5.88M | -4.28M |
| Cash from Operations | -20.18M | -22.02M | -18.31M | -21.62M | -21.50M |
| Capital Expenditure | -2.00K | -378.00K | 2.00K | -35.00K | -201.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 64.00K | 7.00K | 11.00K | -- | -- |
| Cash from Investing | 62.00K | -371.00K | 13.00K | -35.00K | -201.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 216.17M | 75.00K | -- | 6.72M | 70.48M |
| Repurchase of Common Stock | -- | -- | -360.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 118.00K | -127.00K | 3.00K | -127.00K | -13.00K |
| Cash from Financing | 216.29M | -52.00K | -357.00K | 6.60M | 70.47M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 196.17M | -22.44M | -18.65M | -15.06M | 48.76M |